Cambrex, a global CDMO, is investing $120 million to expand its U.S. operations for API development and manufacturing. The investment reflects the company’s efforts to meet the growing demand for peptide therapeutics and critical therapies, and ensure reliable, high-quality manufacturing in the U.S. The $120 million investment will support a 40% increase in the Charles City, IA site’s large-scale manufacturing capacity, reaching nearly one million liters. The Charles City facility, situ...